Archive

Advances in the management of renal cell carcinoma.

Molecular subtyping now refines RCC diagnosis beyond histology, so imaging and selective biopsy decisions increasingly depend on tumour biology rather than stage alone.

Oncology · BMJ · 10d

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Median BICR-assessed progression-free survival 11·1 months (9·2-12·7) with iza-bren versus 5·7 months (5·5-5·9) with chemotherapy; HR 0·40 (95% CI 0·31-0·51), one-sided p<0·0001.

Oncology · Lancet · 10d

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Median progression-free survival 38·2 months versus 8·4 months (HR 0·57, 95% CI 0·42-0·79; p=0·0002). Overall survival interim criterion not met (HR 0·77, 95% CI 0·52-1·15; p=0·10). Grade 3+ treatment-related events 18% versus 51%.

Oncology · Lancet · 10d

Spontaneous Tumor Lysis Syndrome in a Critically Ill Patient With Cytology Favoring Small Cell Carcinoma: A Case Report

Uric acid rose to a documented peak of 12 mg/dL and LDH reached 3,608 U/L, with progressive hyperkalemia, hyperphosphatemia, hypocalcemia, acidosis and anuria; she died of refractory shock and multiorgan failure

Oncology · Cureus · 11d

Contemporary Management of Colorectal Liver Metastases

Resectability is no longer the sole gate: molecular profile and functional liver reserve now decide whether your CRLM patient goes straight to surgery or to conversion therapy first.

Oncology · Cureus · 11d

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

A next-generation KRAS G12C inhibitor beat sotorasib/adagrasib head-to-head in previously treated NSCLC — expect divarasib to enter your second-line sequencing decisions.

Oncology · NEJM · 11d

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.

If the combination beats pembrolizumab-chemotherapy in PD-L1-negative NSCLC, it offers a chemotherapy-sparing first-line option for a group with few good choices.

Oncology · NEJM · 11d

Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.

For EGFR-mutant NSCLC progressing on osimertinib, adding a MET inhibitor targets the commonest resistance mechanism — but requires confirming MET amplification or overexpression first.

Oncology · NEJM · 11d

Comparison of Acute Hematological Toxicities Between Three-Dimensional Conformal Radiotherapy (3DCRT) and Intensity-Modulated Radiotherapy (IMRT) in Locally Advanced Cervical Cancer

During EBRT, overall haematological toxicity was 97.14% with 3DCRT versus 77.14% with IMRT (p = 0.012); leukopenia 65% versus 34% (p = 0.05). After ICRT, overall toxicity 97.14% versus 71.43% (p = 0.006) and anaemia 85.7% versus 51.4% (p = 0.002).

Oncology · Cureus · 12d

Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer.

A HER2 bispecific plus albumin-bound docetaxel may offer a first-line alternative to THP, but wait for the survival and toxicity data before switching regimens.

Oncology · NEJM · 12d

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.

If perioperative durvalumab plus neoadjuvant enfortumab vedotin improves outcomes in cisplatin-ineligible patients, it reshapes who you can offer bladder-sparing curative-intent therapy to.

Oncology · NEJM · 12d

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.

Five-year data confirm the fixed-dose relatlimab-nivolumab combination's durable survival benefit over nivolumab alone, supporting it as a first-line option in untreated advanced melanoma.

Oncology · Nature Medicine · 12d

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.

Adds a GDF-15 antibody to neoadjuvant nivolumab in MIBC; check the pathological response and toxicity data before considering this combination for cisplatin-ineligible patients.

Oncology · Nature Medicine · 12d

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

If halving the FTD-TPI exposure days preserves survival, you can cut haematological and GI toxicity in heavily pretreated patients without sacrificing efficacy.

Oncology · Lancet · 12d

Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.

Median overall survival 21.1 months with tarlatamab-durvalumab versus 12.7 months with durvalumab (HR 0.42; 95% CI 0.32 to 0.54; P<0.001). Median progression-free survival 7.4 versus 1.9 months (HR 0.34; 95% CI 0.28 to 0.42).

Oncology · NEJM · 12d

STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion

If AI-guided discovery using large tumour datasets yields candidates faster, oncology trial options for your patients could widen within a few years.

Oncology · STAT News — Health Tech · 13d

Clinical Outcomes and Safety of Spatially Fractionated Radiotherapy for Malignant Tumors: A Systematic Review and Evidence Map

SFRT delivers ablative central doses with sparing of surrounding tissue; this map shows where comparative evidence is still missing before you adopt it for bulky or radioresistant tumors.

Oncology · Cureus · 13d

Central Nervous System Progression During Longitudinal Treatment of Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer: A Real-World Cohort Study

CNS progression still occurs on CNS-active ALK-TKIs; track cumulative drug exposure across lines, not just first-line choice, when timing MRI surveillance.

Oncology · Cureus · 13d

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.

If the ADC beats physician's-choice chemo in ERBB2-low disease, it opens a targeted option for the large HER2-low group currently offered conventional chemotherapy.

Oncology · JAMA · 13d

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

A first-in-class T cell agonist that targets Vβ6/Vβ10 subsets rather than checkpoint pathways offers a new mechanism for patients whose tumours have already progressed on immunotherapy.

Oncology · Nature Medicine · 13d

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.

Primary DFS endpoint not met: median 23.8 versus 21.2 months (HR 0.85, P = 0.5329). Grade ≥3 adverse events 10.4% versus 14.6%; serious AEs 6.3% versus 8.3%.

Oncology · Nature Medicine · 13d

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma.

High versus low naive-like (CCR7+CD45RA+) T cells in the product gave prolonged PFS: hazard ratio 0.46 (95% CI 0.31-0.68), with no impact on safety.

Oncology · Nature Medicine · 13d

Routes to Diagnosis and Stage at Diagnosis of Colorectal Cancer in Patients Aged ≥ 50 Years: A Multicentre Retrospective Cohort Study From North Wales, UK

Which referral route a patient takes still predicts their CRC stage, so how you triage rectal bleeding and FIT results directly shapes whether they present operable.

Oncology · Cureus · 14d

Extragenital Lichen Sclerosus and Granulomatous Dermatitis in a Patient Treated With Nivolumab and Ipilimumab for Malignant Melanoma: A Case Report

IrAEs can present sequentially over months on dual checkpoint blockade; biopsy unusual rashes rather than assuming a single drug reaction, since management may differ.

Oncology · Cureus · 14d

Clear Skin, Vanishing Brows: Trichoscopy-Confirmed Eyebrow Alopecia Areata Associated With Secukinumab

PASI fell from 36.9 to 15.6 at week 8 and 0 at week 16. Bilateral eyebrow thinning appeared at week 16; trichoscopy showed black dots, circle hairs and short vellus hairs. Regrowth complete three months after stopping.

Oncology · Cureus · 14d

An Unusual Thoracic Presentation of Multiple Myeloma: Rib-Based Paraskeletal Plasmacytoma Mimicking a Lung Mass

Biopsy showed CD38-positive kappa-restricted plasma cells; marrow had 30% clonal plasma cells on trephine immunohistochemistry (15.9% by flow cytometry), with severe anemia and multifocal lytic disease. He died 67 days after admission.

Oncology · Cureus · 21 Oct

Initial Outcomes of GammaTile Brachytherapy From a Single Institution: A Case Series

Implanted at resection, it delivers most radiation before adjuvant therapy would normally start — relevant if you refer brain tumour patients for post-op radiotherapy.

Oncology · Cureus · 21 Oct

Paraneoplastic Hypertrophic Osteoarthropathy in the Setting of Dual Primary Malignancies: Follicular Thyroid Carcinoma and Metastatic Colon Adenocarcinoma

Clubbing and painful periostitis can be the presenting sign of an occult second malignancy; consider paraneoplastic HOA when joint pain accompanies cancer.

Oncology · Cureus · 21 Oct

Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.

3-year disease-free survival was 100% (97·5% CI 100-100) and 5-year overall survival 100% (95% CI 100-100) at median postoperative follow-up of 58·7 months.

Oncology · Lancet · 21 Oct

Short-Course Preoperative Breast Radiotherapy: A Strategy to Reduce Financial Toxicity in Early-Stage Breast Cancer

No primary outcome reported. Five-fraction APBI is described as economically advantageous yet underutilised; whether preoperative radiotherapy reduces financial toxicity remains uncertain, and the institutional savings estimate is unpublished and not validated by time-driven activity-based costing

Oncology · Cureus · 21 Oct

Myocardial Infarction in a Patient With Chronic Lymphocytic Leukemia: Acalabrutinib-Related Dehoming as a Potential Culprit

STEMI occurred 28 days after acalabrutinib initiation, with absolute lymphocyte count 261 x 109/L on admission. Course included cardiac arrest, third-degree AV block needing temporary pacing, PCI with IABP, and parietal and occipital strokes; she was discharged home.

Oncology · Cureus · 20 Oct

Standalone Complete Decongestive Therapy Versus Combined Treatment With Kinesio Taping for Reducing Upper Limb Breast Cancer-Related Lymphedema After Axillary Dissection: A Randomized Clinical Trial

Adding kinesio taping to decongestive therapy was tested against CDT alone in 40 post-axillary-dissection women — know whether the extra taping buys measurable limb volume before you refer.

Oncology · Cureus · 20 Oct

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery

For dMMR locally advanced rectal cancer, dostarlimab now offers a non-surgical path — worth checking mismatch repair status before referring for chemoradiation.

Oncology · FDA — Press Announcements · 19 Oct

How MRD is powering the next wave of precision oncology

MRD testing after curative-intent therapy can flag residual disease before imaging does, so you may soon be choosing adjuvant escalation or de-escalation on a blood test rather than a scan.

Oncology · Fierce Healthcare · 19 Oct

Pembrolizumab-Associated Adrenal Insufficiency Presenting as Adrenal Crisis: A Case Report

Check cortisol in any pembrolizumab patient with hypotension or hyponatraemia — immune adrenalitis can present as crisis even after the drug is stopped.

Oncology · Cureus · 19 Oct

Transformation of Mixed Cellularity Classical Hodgkin Lymphoma to Diffuse Large B-cell Lymphoma: A Case Report and Literature Review

Histologic transformation from mixed cellularity classical Hodgkin lymphoma to DLBCL occurred after transplant and relapse; the patient was then treated with polatuzumab vedotin, rituximab and ibrutinib. No outcome data are reported.

Oncology · Cureus · 19 Oct

Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.

Genomic and epigenomic profiling may identify which quadruplet-treated myeloma patients will clear MRD, letting you intensify or de-escalate induction earlier.

Oncology · Nature Medicine · 19 Oct

Pleural Metastasis in Epithelioid Angiosarcoma

Imaging and biopsy showed metastatic epithelioid angiosarcoma involving liver, spleen and pleura; she received palliative care, VATS and pleurodesis. No outcome figures reported.

Oncology · Cureus · 18 Oct

Shared Care Models for Cancer Survivorship: A Narrative Review of What Works, for Whom, and Why

If your cancer follow-up clinic is overrun, this maps which survivorship tasks can safely shift to general practice, nursing and pharmacy, and for which patients.

Oncology · Cureus · 17 Oct

EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.

A single convection-enhanced infusion of this dual EGFR/EGFRvIII toxin was tested in 81 recurrent glioma patients; watch for phase 2 efficacy and neurotoxicity data before considering referral.

Oncology · Nature Medicine · 16 Oct